Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy
Kidney and Blood Pressure Research · 17.03.2025 · 50 (1) · 267-275
DOI: 10.1159/000545286 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney and Blood Pressure Research, online erschienen am 17.03.2025. Verfasst von Justine Huart und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Liège Hospital (ULiège CHU), Liège, Belgium. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Mineralocorticoid Receptor Antagonists, Naphthyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease worldwide. The management of DKD relies on controlling glycemia and blood pressure levels, as well as reducing proteinuria. While the traditional renin-angiotensin-aldosterone system inhibitors (RAASi) and the recently approved type 2 Na+/glucose co-transporter inhibitors (SGLT2i) have significantly improved patient outcomes, residual risks remain unaddressed. Summary: This review explores (1) the mechanisms of action of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (ns-MRA), (2) the evidence of finerenone-induced kidney protection in clinical trials, and (3) the comparative advantages over conventional MRAs. The potential synergy between finerenone and SGLT2i is also addressed, alongside research perspectives and practical considerations for implementation in clinical practice. Key Messages: Finerenone has emerged as a breakthrough therapy in the management of DKD, demonstrating robust nephro- and cardio-protective effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, University of Liège Hospital (ULiège CHU), Liège, Belgium.
- Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Metabolism and Cardiovascular Biology, Laboratory of Translational Research in Nephrology, University of Liège, Liège, Belgium.
Zitieren
APA
Huart, J., & Jouret, F. (2025). Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy. Kidney and Blood Pressure Research, 50(1), 267-275. https://doi.org/10.1159/000545286
Vancouver
Huart J, Jouret F. Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy. Kidney and Blood Pressure Research. 2025;50(1):267-275. doi:10.1159/000545286
BibTeX
@article{Huart2025,
author = {Huart, Justine and Jouret, François},
title = {Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy},
journal = {Kidney and Blood Pressure Research},
year = {2025},
volume = {50},
number = {1},
pages = {267--275},
doi = {10.1159/000545286}
}
EUVIMED